Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Product |
Terms/Details (Date) |
| | |||
Alliance Pharmaceutical Corp. (OTC BB:ALLP) |
IL Yang Pharmaceutical Co. Ltd. (South Korea) |
IL Yang got exclusive rights to distribute and commercialize Oxygent in South Korea |
Alliance would get royalties from sales of the blood substitute, and milestones for regulatory progress in the U.S. and Europe (4/19) |
Amylin Pharmaceuticals Inc. (AMLN) |
Reliant Pharmaceuticals Inc. |
Amylin will co-promote Reliant's products for cholesterol management and hypertension |
The deal is expected to allow Amylin to leverage its sales efforts in diabetes; terms were not disclosed (4/8) |
Artus GmbH* (Germany) |
Abbott Laboratories |
Expanded Abbott's distribution rights to all of Artus' nucleic acid-based diagnostics for use on Applied Biosystems instruments |
Abbott is expanding the menu of tests it offers by adding Artus tests for several infectious diseases, which it will offer on the Applied Biosystems platform (4/14) |
AVAX Technologies Inc. (OTC BB:AVXT) |
OPi SAS (France) |
Manufacturing alliance between AVAX unit Genopoeitic and OPi unit Opisodia SAS |
AVAX is getting $1.5M for each of the next two years under the deal in which products for both companies will be produced (2/24) |
Cartagen Molecular Systems Inc.* |
Entest Japan Inc. (Japan) |
Deal to develop a market presence for Cartagen's nucleic acid- separation products in Japan |
Terms of the deal were not disclosed (3/9) |
Chiral Quest Inc. (OTC BB:CQST) |
Strem Chemicals Inc. |
Several of Chiral Quest's ligand products |
Strem Chemicals was named a distributor of the products (3/8) |
Chromos Molecular Systems Inc. (Canada; TSE:CHR) |
Lonza Biologics plc (UK) |
Extended agreement providing Lonza nonexclusive access to Chromos' ACE System for evaluation in contract manufacturing |
The extension runs to 4Q:04, and carries an option to license Chromos' ACE System with Lonza's GS System for use in cellular protein production (3/30) |
Cobra Bio- manufacturing plc (UK; LSE:CBF) |
AstraZeneca plc (UK) |
Cobra will supply Astra- Zeneca licenses to DNA manufacturing technology |
AstraZeneca will use the technology in support of identification and evaluation of drug targets; terms were not disclosed (3/30) |
Diversa Inc. (DVSA) |
Fermic SA de CV (Mexico) |
Fermic will provide manufacturing capacity for production of Diversa's enzyme products |
Diversa will co-invest in certain capital equipment in exchange for credits for manufacturing services; specific terms of the long-term deal were not disclosed (2/23) |
EraGen Biosciences Inc.* |
Inter Medico (Canada) |
Inter Medico will distribute EraGen's molecular diagnostic products in Canada |
Inter Medico's rights are exclusive in Canada; terms were not disclosed (3/15) |
GlycoFi Inc.* |
Eli Lilly and Co. |
Deal to evaluate GlycoFi's yeast-based platform for producing an undisclosed protein |
Lilly will support the effort; terms of the deal were not disclosed (4/8) |
GTC Biotherapeutics Inc. (GTCB) |
Laureate Pharma LP |
Companies will coordinate efforts to provide recombinant protein production services |
No initial payments were made in the deal, terms of which were not disclosed (3/9) |
Immtech International Inc. (AMEX:IMM) |
Cambrex Charles City Inc. |
Agreement for Cambrex to develop an enhanced process for manufacturing DB289, a Phase II drug in malaria and other infectious diseases |
Cambrex is expected to manufacture the substance in bulk after developing the synthesis method; terms were not dis- closed (3/17) |
Interleukin Genetics Inc. (OTC BB:ILGN) |
Access Business Group International LLC (subsidiary of Alticor Inc.) |
Distribution agreement for DNA- ased risk-assessment tests |
The deal with Access triggered a $2M payment from Alticor to Interleukin Genetics under a deal they entered in March 2003 (3/16) |
Jerini AG* (Germany) |
Bachem AG (Switzerland) |
Agreement for the production and supply of Jerini's Icatibant, a peptidomimetic in Phase II |
Bachem will provide manufacturing services for the bradykinin antagonist under undisclosed terms (3/18) |
Labopharm Inc. (Canada; TSE:DDS) |
Hexal AG (Germany) |
Hexal gets the the right to market Labopharm's formulation of tramadol in Germany |
Labopharm is responsible for obtaining regulatory approval in Germany; terms of the revenue-sharing deal were not disclosed (3/31) |
Large Scale Biology Corp. (LSBC) |
Sigma-Aldrich Fine Chemicals |
Manufacturing and distribution deal for LSBC's plant-produced recombinant aprotinin product Apronexin |
LSBC will manufacture the protease inhibitor and Sigma-Aldrich will distribute it to the R&D, cell culture and manufacturing markets under the multiyear deal (3/4) |
Ligand Pharmaceuticals Inc. (LGND) |
NV Organon (the Netherlands) |
Companies will expand their sales efforts related to the pain drug Avinza |
They will increase sales calls 50% and establish a specific effort to cover the long-term care/hospice segment of the market (3/31) |
Ligand Pharmaceuticals Inc. (LGND) |
Hollister-Stier Laboratories LLC |
Hollister-Stier will provide fill/ finish work for Ontak and a second- generation formulation |
The five-year deal was made with Ligand subsidiary Seragen Inc., and can be extended two years by Ligand; terms were not disclosed (3/3) |
Ligand Pharmaceuticals Inc. (LGND) |
Cardinal Health Inc. |
Cardinal will manufacture and package Ligand's Avinza |
Ligand has an option to extend the five- year deal two additional years; terms were not disclosed (3/3) |
Microbia Inc.* |
Teva Pharmaceutical Industries Ltd. (Israel) |
Multiyear, multiproduct expansion of deal to develop improved biomanufacturing processes |
The deal centers on Microbia's Precision Engineering technology; Teva will fund Microbia's efforts and make undisclosed milestone and royalty payments (3/29) |
Micromet AG* (Germany) |
Boehringer Ingelheim GmbH (Germany) |
Deal for the process development and production of Micromet's fully human MT201 antibody |
BI will supply material for clinical trials and future commercialization for the Phase II prostate cancer product; Micromet may license BI's high- xpression technology for manufacturing MT201, while BI gets an option for commercial manufacturing of MT201 (2/25) |
NeoPharm Inc. (NEOL) |
Diosynth Biotechnology (unit of Akzo Nobel NV) |
Diosynth will manufacture interleukin-13-PE38QQR for NeoPharm's Phase III trials |
The drug is being tested in glioblastoma multiforme; terms of the deal were not disclosed (4/7) |
NovImmune SA* (Switzerland) |
Lonza Group AG (Switzerland) |
Deal for the production and supply of clinical-grade monoclonal antibody drugs |
Lonza will manufacture the products of NovImmune and its partners, all the way to marketing; terms were not disclosed (2/20) |
Provalis plc (UK; LSE:PRO) |
Edmond Pharma SpA (Italy) |
Deal for Provalis to distribute the mucolytic agent Erdotin in the UK and Ireland |
Provalis is paying €200,000 toward development and regulatory costs, against certain regulatory milestones; the product has been available in other Eurpopean markets (4/19) |
Raven Biotechnologies Inc.* |
AppTec Laboratory Services Inc. |
Deal for process development and manufacturing of Raven's RAV12 monoclonal antibody |
The deal gives Raven flexibility regarding preclinical and future clinical supplies of the cancer product; terms were not dis- closed (4/14) |
RNAx GmbH* (Germany) |
Funakoshi Ltd. (Japan) |
Funakoshi will be exclusive agent for RNAx in Japan |
The deal relates to RNAx services for validation of siRNA oligonucleotides and genetic targets based on RNAi technology (3/26) |
Seattle Genetics Inc. (SGEN) |
Abbott Laboratories |
Deal for the manufacturing of Seattle Genetics' SGN-30 monoclonal antibody product |
Abbott will perform scale-up and GMP manufacturing for trials, and would supply commercial-grade material to support any sales; terms were not disclosed. (2/24) |
Y's Therapeutics (Japan) |
Lonza Group Ltd. (Switzerland) |
Collaboration on cell line construction of a humanized monoclonal antibody for Y's YSCMA program in cancer and immune diseases |
Y's gets access to Lonza's GS Gene Expression System for creating a cell line and to antibody manufacturing expertise; terms were not disclosed (4/6) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
